Meiji Seika Pharma to Showcase Nacubactam Data at ESCMID Global 2026
Event summary
- Meiji Seika Pharma will present 10 studies on nacubactam at ESCMID Global 2026, including Phase III Integral-2 results.
- Nacubactam is under review for manufacturing and marketing approval in Japan.
- The drug targets carbapenem-resistant Enterobacterales (CRE), a global health threat.
- Integral-2 trial confirmed high efficacy of cefepime/nacubactam and aztreonam/nacubactam compared to best available therapy.
The big picture
Meiji Seika Pharma's nacubactam is poised to address a critical gap in treating carbapenem-resistant infections, a growing global health concern highlighted by the WHO. The drug's unique mechanism of action and positive Phase III trial results position it as a potential key player in the fight against antimicrobial resistance. The upcoming presentations at ESCMID Global 2026 will be crucial in validating its clinical and commercial potential.
What we're watching
- Regulatory Approval
- Whether nacubactam will secure manufacturing and marketing approval in Japan by the end of 2026.
- Clinical Efficacy
- How the Phase III Integral-2 results will impact nacubactam's market positioning against existing treatments.
- Global Expansion
- The pace at which Meiji Seika Pharma can expand nacubactam's reach beyond Japan.
Related topics